Anita Pye

Dr. Anita Pye

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
DSDaniel Smith
Daniel Smith
AGArran Gill
Arran Gill
LHLewis Hall
Lewis Hall
APAnita Pye
Anita Pye
A concern of antibiotic use in chronic obstructive pulmonary disease (COPD) is the emergence and propagation of antimicrobial resistance (AMR). A systematic review was conducted to determine prevalence, pattern, risk factors and consequences of AMR in COPD. Bibliographic databases were searched from inception to November 2020, with no language restrictions, including studies of any design that included patients with COPD and reported prevalence and pattern of AMR. 2748 unique titles and abstracts were identified, of which 63 articles, comprising 26,387 patients, met inclusion criteria. Forty-four (69.8%) studies were performed during acute exacerbation. The median prevalence of AMR ranged from 0–100% for Pseudomonas aeruginosa, Moraxella catarrhalis, Klebsiella pneumoniae and Acinetobacter baumannii. Median resistance rates of H influenzae and S pneumoniae were lower by comparison, with maximum rates ≤40% and ≤46%, respectively, and higher for Staphylococcus aureus. There was a trend towards higher rates of AMR in patients with poorer lung function and greater incidence of previous antibiotic exposure and hospitalisation. The impact of AMR on mortality was unclear. Data regarding antimicrobial susceptibility testing techniques and the impact of other risk factors or consequences of AMR were variable or not reported. This is the first review to systematically unify data regarding AMR in COPD. AMR is relatively common and strategies to optimise antibiotic use could be valuable to prevent the currently under-investigated potential adverse consequences of AMR. Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.2000957 .

1 December 2020 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
MQMark Quinn
Mark Quinn
PEPaul Ellis
Paul Ellis
APAnita Pye
Anita Pye
Alice M TurnerAlice M Turner
Alice M Turner
This review summarizes the current research and outlooks regarding the obstacles to diagnosing and treating early alpha-1-antitrypsin deficiency (AATD). It draws on prior systematic reviews and expert surveys to discover precisely what difficulties exist in early diagnosis and treatment of AATD and elucidate potential solutions to ease these difficulties. The perceived rarity of AATD may translate to a condition poorly understood by primary care physicians, and even many respiratory physicians, which results in opportunities for diagnosis being missed, especially in mild or asymptomatic patients. There are diagnostic techniques involving biomarkers and home testing methods which could improve the rate of early diagnosis. With respect to treatment, AATD involves treating two separate pathologies, lung disease and liver disease. The only specific AATD treatment, augmentation therapy, has proven ability in treating lung disease but not liver disease. Alpha-1-antitrypsin (AAT) synthesized in the liver can form damaging polymers that also result in reduced circulating AAT levels and, whilst liver transplantation is used to effectively treat AATD, it is inappropriate in early disease. Novel therapeutic areas such as gene editing and increasing autophagy are therefore being researched as future treatments. Ultimately, diagnosis and treatment are intrinsically linked in AATD, with earlier diagnosis leading to better treatment options and thus better patient outcomes.

3 October 2019 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Open access
APAnita Pye
Anita Pye
Alice M TurnerAlice M Turner
Alice M Turner
Introduction Alpha-1 antitrypsin deficiency (AATD) is most often associated with chronic lung disease, early onset emphysema and liver disease. The standard of care in lung disease due to AATD is alpha-1 antitrypsin augmentation but there are several new and emerging treatment options under investigation for both lung and liver manifestations. Areas covered We review therapeutic approaches to lung and liver disease in alpha-1 antitrypsin deficiency (AATD) and the agents in clinical development according to their mode of action. The focus is on products in clinical trials, but data from pre-clinical studies is described where relevant, particularly where progression to trials appears likely. Expert opinion Clinical trials directed at lung and liver disease separately are now taking place. Multimodality treatment may be the future, but this could be limited by treatment costs. The next 5-10 years may reveal new guidance on when to use therapeutics for slowing disease progression with personalized treatment regimes coming to the forefront.

6 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KPKetan Patel
Ketan Patel
DSDaniel J Smith
Daniel J Smith
CHChristopher C Huntley
Christopher C Huntley
SCSunita D Channa
Sunita D Channa
APAnita Pye
Anita Pye
Alice M TurnerAlice M Turner
Alice M Turner
Background: Within primary care there exists a cohort of patients misdiagnosed with Chronic Obstructive Pulmonary Disease (COPD). Misdiagnosis can have a detrimental impact on healthcare finances and patient health and so understanding the factors leading to misdiagnosis is crucial in order to reduce misdiagnosis in the future. The objective of this study is to understand and explore the perceived causes of COPD misdiagnosis in primary care. Methods: A sequential mixed methods study, quantifying prevalence and features of patients misdiagnosed with COPD in primary care followed by a qualitative analysis to explore perceived causes of misdiagnosis. Quantitative data was collected for 206 patients identified as misdiagnosed with COPD within the INTEGR COPD study (NCT03482700). Qualitative data collected from 21 healthcare professionals involved in providing COPD care and 8 misdiagnosed patients who were recruited using a maximum variation purposive sampling. Results: Misinterpretation of spirometry results was the prevailing factor leading to patients initially being misdiagnosed with COPD, affecting 59% of misdiagnosed patients in this cohort. Of the 99 patients who were investigated for their underlying diagnosis; 41% had normal spirometry and 40% had asthma. Further investigation through qualitative methodology uncovered reluctance to challenge historical misdiagnoses and challenges in differential diagnosis as the underlying explanations for COPD misdiagnosis in this cohort. Conclusions: Patients historically diagnosed with COPD without spirometric evidence are at risk of remaining labelled and treated for COPD despite non-obstructive respiratory physiology, leading to a persistent cohort of patients misdiagnosed with COPD in primary care. The lack of spirometry services during and after the COVID19 pandemic in primary care risks adding to the cohort of misdiagnosed patients. Support from respiratory specialists can potentially help to reduce the prevalence of COPD misdiagnosis in primary care. Trial registration: NCT03482700.

1 January 1994 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
SHS. L. Hill
S. L. Hill
DBD. Bilton
D. Bilton
MJM. M. Johnson
M. M. Johnson
APAnita Pye
Anita Pye
JMJ. L. Mitchell
J. L. Mitchell
RSR. A. Stockley
R. A. Stockley
Sputum and serum pharmacokinetics of loracarbef (LY 163892) were performed in 19 patients with purulent bronchiectasis. Nine of the patients received 200 mg twice daily and ten patients, 400 mg twice daily, for a total of 14 days. β-Lactamase activity was measurable in the lung secretions of all 19 patients at the start of therapy. Mean peak serum concentrations of 11.7 mg/L (S.E.M. 1.7) were recorded at 1 h after administration of 200 mg doses on day 2 of therapy and were 18.5 mg/L (S.E.M. 1.9) at 1.5 h in the 400 mg group. Loracarbef was shown to penetrate lung secretions even in the presence of β-lactamase activity. Mean peak sputum concentrations were achieved between 2 and 4 h following dosing and were 0.2 mg/L (S.E.M. 0.05) in the 200 mg group and 0.4 mg/L (S.E.M. 0.08) in the 400 mg group. On days 7 and 14 of therapy, sputum loracarbef concentrations were similar 4 h after the morning dose (0.23 mg/L following 200 mg; 0.35 mg/L after 400 mg). These concentrations were approximately 2% of the peak serum concentration and penetration into lung secretions is similar to other beta-lactams.

4 March 2025 in Respiratory Medicine
Verified
Journal Article
Open access
DSDaniella A. Spittle
Daniella A. Spittle
APAnita Pye
Anita Pye
JSJan Stanka
Jan Stanka
JSJoshua De Soyza
Joshua De Soyza
RSRobert A. Stockley
Robert A. Stockley
ATAlice M. Turner
Alice M. Turner
Pulmonary exacerbations in alpha-1 antitrypsin deficiency (AATD) are associated with worse disease outcomes, including accelerated lung function decline. As with non-deficient COPD, subjects with AATD are predisposed to bacterial colonisation of the lower respiratory tract, a known risk factor for exacerbations. Despite this, the extent to which colonising bacteria contribute to exacerbations remains relatively unexplored. Sputum samples were collected longitudinally from AATD subjects, when clinically stable and during exacerbations, and were processed for quantitative culture to identify bacterial pathogens. Using contemporaneous clinical data, a post-hoc analysis was performed to calculate the odds of an exacerbation in the presence of recognised, potentially pathogenic bacteria (PPB) of the lower respiratory tract. 324 sputum samples were collected from 29 patients with AATD plus radiological evidence of bronchiectasis and 671 samples from 62 patients without bronchiectasis (AATD alone). Both groups contained patients with AATD-associated lung disease (emphysema and chronic bronchitis). At least half of the samples (55.5%) from AATD alone were positive for a PPB and almost three quarters (72.8%) of those with bronchiectasis. Presence of a Pseudomonas species, Staphylococcus aureus or Moraxella catarrhalis during stable state disease were all significantly associated with increased likelihood of a subsequent exacerbation (OR: 1.89, p=0.0013; 1.98, 0.0022; 1.98, 0.0047; 2.19, 0.0047, respectively), independent of age, sex, disease severity (FEV1 impairment), smoking status and presence or absence of bronchiectasis. Disease progression in AATD is variable and identification of traits which may contribute may prove influential. Here, we report that bacterial colonisation is an important predictor of exacerbation in AATD, likely attributed to the associated levels of increased inflammation. Thereby, this may represent a sub cohort of patients that could benefit from additional, targeted therapy.